A Prospective Nonrandomized Study of Autologous Muscle Derived Cell (AMDC) Transplantation for Treatment of Fecal Incontinence
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Autologous muscle-derived stem cell therapy Cook MyoSite (Primary)
- Indications Faecal incontinence
- Focus Adverse reactions
- Sponsors Cook Medical; Cook MyoSite
- 21 Oct 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 21 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 15 Oct 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov record.